文献速递肿瘤 PET/CT核素与放射性配体治疗

免疫组化FAP表达反映低级别与高级别导管内乳头状黏液性肿瘤及胰腺导管腺癌的68Ga-FAPI PET显像特性

Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · J Nucl Med · 2024-01-02

研究对2017至2023年在海德堡大学医院接受胰腺手术的98例低级别IPMN、高级别IPMN、高级别IPMN合并PDAC或PDAC患者的294份标本行FAP与αSMA免疫组化染色半定量评分,并与其中14例既往68Ga-FAPI-74 PET/CT的SUVmax、SUVmean及TTP对比,发现FAP表达随恶性程度升高而增加并与PET参数匹配,验证FAP为基于生物学基质的在体显像靶点。

要点

  • 98例患者294份标本中肿瘤基质FAP均呈不同程度阳性。
  • FAP染色强度、阳性基质百分比、IRS及Her2/neu评分随恶性程度升高而增加。
  • 14例FAP IRS均值与68Ga-FAPI-74 PET的SUVmax、SUVmean及TTP随恶性程度升高呈匹配变化。

核心结论

  • IPMN与PDAC的免疫组化染色验证FAP可作为基于生物学基质的在体显像靶点。
  • 高级别病变中FAP表达增加,与PDAC和高级别IPMN中FAP表达强于低级别IPMN的预期相符,并印证了既往PDAC和高级别IPMN较LG IPMN SUV更高、TTP更长的发现。

研究设计与样本

  • 研究纳入2017至2023年在海德堡大学医院接受胰腺手术的98例低级别IPMN、高级别IPMN、高级别IPMN合并PDAC或PDAC患者。
  • 对石蜡包埋切除标本重新行苏木精-伊红染色并按现行两级分级方案重新分级,取消原有「中度异型增生IPMN」诊断。
  • 每例取3个含肿瘤石蜡块的半薄切片行FAP与αSMA免疫组化染色,由病理科医师采用免疫反应评分(IRS)及人表皮生长因子受体2(Her2)/neu评分行半定量分析。
  • 将既往研究中14例接受68Ga-FAPI-74 PET/CT患者的IRS与SUVmax、SUVmean及TTP比较以验证结果。

主要发现

  • 98例患者共294份标本(每例3份重复)行FAP与αSMA免疫组化染色。
  • 23例为低级别IPMN,11例为高级别IPMN,10例为高级别IPMN合并PDAC,54例为PDAC。
  • 所有病例肿瘤基质FAP均呈不同程度阳性,FAP染色强度、阳性基质百分比、IRS及Her2/neu评分随恶性程度升高而增加。
  • αSMA表达见于正常胰腺基质及肿瘤周围和肿瘤内促纤维增生反应中,αSMA的强度、百分比、IRS及Her2/neu评分未随恶性程度升高呈均一增加。
  • 14例患者FAP平均IRS与68Ga-FAPI-74 PET/CT平均SUVmax、SUVmean及TTP比较显示,随恶性程度升高,PET显像与免疫组化FAP表达呈匹配的数值增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pancreatic intraductal papillary mucinous neoplasms (IPMNs) are grossly visible (typically > 5 mm) intraductal epithelial neoplasms of mucin-producing cells, arising in the main pancreatic duct or its branches. According to the current 2-tiered grading scheme, these lesions are categorized as having either low-grade (LG) dysplasia, which has a benign prognosis, or high-grade (HG) dysplasia, which formally represents a carcinoma in situ and thus can transform to pancreatic ductal adenocarcinoma (PDAC). Because both entities require different treatments according to their risk of becoming malignant, a precise pretherapeutic diagnostic differentiation is inevitable for adequate patient management. Recently, our group has demonstrated that 68Ga-fibroblast activation protein (FAP) inhibitor (FAPI) PET/CT shows great potential for the differentiation of LG IPMNs, HG IPMNs, and PDAC according to marked differences in signal intensity and tracer dynamics. The purpose of this study was to biologically validate FAP as a target for PET imaging by analyzing immunohistochemical FAP expression in LG IPMNs, HG IPMNs, and PDAC and comparing with SUV and time to peak (TTP) measured in our prior study. Methods: To evaluate the correlation of the expression level of FAP and α-smooth muscle actin (αSMA) in neoplasm-associated stroma depending on the degree of dysplasia in IPMNs, 98 patients with a diagnosis of LG IPMN, HG IPMN, PDAC with associated HG IPMN, or PDAC who underwent pancreatic surgery at the University Hospital Heidelberg between 2017 and 2023 were identified using the database of the Institute of Pathology, University Hospital Heidelberg. In a reevaluation of hematoxylin- and eosin-stained tissue sections of formalin-fixed and paraffin-embedded resection material from the archive, which was originally generated for histopathologic routine diagnostics, a regrading of IPMNs was performed by a pathologist according to the current 2-tiered grading scheme, consequently eliminating the former diagnosis of "IPMN with intermediate-grade dysplasia." For each case, semithin tissue sections of 3 paraffin blocks containing neoplasm were immunohistologically stained with antibodies directed against FAP and αSMA. In a masked approach, a semiquantitative analysis of the immunohistochemically stained slides was finally performed by a pathologist by adapting the immunoreactive score (IRS) and human epidermal growth factor receptor 2 (Her2)/neu score to determine the intensity and percentage of FAP- and αSMA-positive cells. Afterward, the IRS of 14 patients who underwent 68Ga-FAPI-74 PET/CT in our previous study was compared with their SUVmax, SUVmean, and TTP for result validation. Results: From 98 patients, 294 specimens (3 replicates per patient) were immunohistochemically stained for FAP and αSMA. Twenty-three patients had LG IPMNs, 11 had HG IPMNs, 10 had HG IPMNs plus PDAC, and 54 had PDAC. The tumor stroma was in all cases variably positive for FAP. The staining intensity, percentage of FAP-positive stroma, IRS, and Her2/neu score increased with higher malignancy. αSMA expression could be shown in normal pancreatic stroma as well as within peri- and intraneoplastic desmoplastic reaction. No homogeneous increase in intensity, percentage, IRS, and Her2/neu score with higher malignancy was observed for αSMA. The comparison of the mean IRS of FAP with the mean SUVmax, SUVmean, and TTP of 68Ga-GAPI-74 PET/CT showed a matching value increasing with higher malignancy in 68Ga-FAPI-74 PET imaging and immunohistochemical FAP expression. Conclusion: The immunohistochemical staining of IPMNs and PDAC validates FAP as a biology-based stromal target for in vivo imaging. Increasing expression of FAP in lesions with a higher degree of malignancy matches the expectation of a stronger FAP expression in PDAC and HG IPMNs than in LG IPMNs and corroborates our previous findings of higher SUVs and a longer TTP in PDAC and HG IPMNs than in LG IPMNs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Spektor AM, Gutjahr E, Lang M, et al. Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2024. PMID: 38167622. doi:10.2967/jnumed.123.266393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。